Joshua B. Rubin, M.D., Ph.D.  rubin_j@kids.wustl.edu

Profile picture
Professor of Pediatrics, Hematology and Oncology
Professor, Neurology
Professor, Neuroscience
Hematology and Oncology

phone: (314) 454-6018

Education

  • MD, Albert Einstein College of Medicine1994
  • PhD, Albert Einstein College of Medicine1994
  • BS, Yale University1982
  • MSc, Albert Einstein College of Medicine1992

Training

  • Internship in Pediatrics, Boston Children's Hospital1994 - 1995
  • Residency in Pediatrics, Boston Children's Hospital1995 - 1997
  • Fellowship in Pediatric Hematology and Oncology, Dana Farber Cancer Institute and Boston Children's Hospital1997 - 2000
  • Post-Doctoral Fellow, Dana Farber Cancer Institute1998 - 2003

Licensure and Board Certification

  • MA, MA 1994
  • MO 2003
  • American Board of Pediatrics, sub-board in Pediatric Hematology/Oncology 2004

Honors

  • Alpha Omega Alpha1993
  • NICHD Scholar of the Child Health Research Center for Excellence in developmental biology at Washington University School of Medicine2003
  • Andrew Hennessey Memorial Award for Scientific Research2005
  • Elected Member, Society for Pediatric Research2008 - Pres
  • Hyundai Scholar2008
  • Top 10 Percent Washington University School of Medicine Faculty on patient satisfaction surveys2008
  • Hyundai Scholar2013 - 2015
  • Pioneer Award in Pediatric Neuro-Oncology from the Children's Brain Tumor Foundation2018 - Pres

Recent Publications view all (89)


Publication Co-Authors

  1. Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer. 2018. PMID:30152087 
  2. Sex-specific gene and pathway modeling of inherited glioma risk. Neuro Oncol. 2018. PMID:30124908 
  3. Focused ultrasound-enabled delivery of radiolabeled nanoclusters to the pons. J Control Release. 2018;283:143-150. PMCID:PMC6035767  PMID:29864474 
  4. Altered hemodynamics contribute to local but not remote functional connectivity disruption due to glioma growth Journal of Cerebral Blood Flow and Metabolism. 2018. 
  5. Focused ultrasound combined with microbubble-mediated intranasal delivery of gold nanoclusters to the brain. J Control Release. 2018. PMID:30009893 
  6. Focused Ultrasound Enabled Trans-Blood Brain Barrier Delivery of Gold Nanoclusters: Effect of Surface Charges and Quantification Using Positron Emission Tomography. Small. 2018;e1703115. PMID:29966035 
  7. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Sci Rep. 2018;8(1):7352. PMCID:PMC5943590  PMID:29743610 
  8. Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Neuro Oncol. 2018. PMID:29741745 
  9. Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. Cold Spring Harb Mol Case Stud. 2018;4(2). PMCID:PMC5880262  PMID:29440180 
  10. Females have the survival advantage in glioblastoma. Neuro Oncol. 2018;20(4):576-577. PMCID:PMC5909625  PMID:29474647 
  11. A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration. Nat Med. 2018;24(3):338-351. PMCID:PMC5908710  PMID:29431744 
  12. Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathol Commun. 2018;6(1):12. PMCID:PMC5819173  PMID:29458417 
  13. Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. Cancer Cell. 2018;33(2):292-308.e7. PMCID:PMC5813693  PMID:29438698 
  14. Pediatric low-grade gliomas: a brave new world. Neuro Oncol. 2018;20(2):149-150. PMCID:PMC5777489  PMID:29365202 
  15. Fetal microchimerism in human brain tumors. Brain Pathology. 2017. PMID:28921714 
  16. Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors. Genes Cancer. 2017;8(9-10):725-744. PMCID:PMC5724806  PMID:29234490 
  17. Sexual dimorphism in glioma glycolysis underlies sex differences in survival. JCI Insight. 2017;2(15). PMID:28768910 
  18. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31(6):737-754.e6. PMID:28609654 
  19. Cell-intrinsic, Bmal1-dependent Circadian Regulation of Temozolomide Sensitivity in Glioblastoma. J Biol Rhythms. 2017;32(2):121-129. PMID:28470120 
  20. Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4. Cancer Res. 2017;77(6):1416-1426. PMCID:PMC5505622  PMID:28031228 
  21. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun. 2016;4(1):93. PMCID:PMC5006436  PMID:27577993 
  22. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma. Cancer Cell. 2016;29(5):669-83. PMID:27165742 
  23. Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk. Mol Cell Oncol. 2016;3(3):e1069917. PMCID:PMC4909402  PMID:27314079 
  24. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17(4):484-95. PMCID:PMC4907853  PMID:26976201 
  25. The Fallacy of Univariate Solutions to Complex Systems Problems. Front Neurosci. 2016;10:267. PMID:27375425 
  26. Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions. Oncotarget. 2015;6(21):18282-92. doi:10.18632/oncotarget.4957  PMID:26286961 
  27. Sexual selection and cancer biology. Oncotarget. 2015;6(18):15714-5. PMCID:PMC4599216  PMID:26158217 
  28. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Res. 2015;75(1):16-21. doi:10.1158/0008-5472.CAN-14-1891  PMCID:PMC4286430  PMID:25381154 
  29. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014;2:174. doi:10.1186/s40478-014-0174-y  PMCID:PMC4297452  PMID:25539912 
  30. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget. 2014;5(20):9811-22. doi:10.18632/oncotarget.2443  PMCID:PMC4259439  PMID:25238146 
  31. Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. J Clin Invest. 2014;124(9):4123-33. doi:10.1172/JCI71048  PMCID:PMC4151215  PMID:25083989 
  32. The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014;20(9):1035-42. doi:10.1038/nm.3666  PMID:25150496 
  33. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014;46(5):462-6. doi:10.1038/ng.2950  PMID:24705250 
  34. Reply: To PMID 24375753. Ann Neurol. 2014;75(5):800-1. PMID:24752946 
  35. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61(4):636-42. doi:10.1002/pbc.24794  PMID:24123865 
  36. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32(9):886-96. doi:10.1200/JCO.2013.50.9539  PMCID:PMC3948094  PMID:24493713 
  37. Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 2014;75(2):309-16. PMCID:PMC4172335  PMID:24375753 
  38. PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells. PLoS One. 2014;9(9):e107397. doi:10.1371/journal.pone.0107397  PMCID:PMC4159344  PMID:25203500 
  39. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013;126(6):917-29. doi:10.1007/s00401-013-1198-2  PMCID:PMC3830749  PMID:24174164 
  40. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013. doi:10.1200/JCO.2012.48.5052  PMID:23835706 
  41. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013;74(3):136-41. doi:10.1055/s-0033-1338262  PMCID:PMC3709924  PMID:24436903 
  42. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer. 2013;12:18. doi:10.1186/1476-4598-12-18  PMCID:PMC3599655  PMID:23497290 
  43. F11R is a novel monocyte prognostic biomarker for malignant glioma. PLoS One. 2013;8(10):e77571. doi:10.1371/journal.pone.0077571  PMCID:PMC3795683  PMID:24147027 
  44. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Fam Cancer. 2012;11(4):653-6. doi:10.1007/s10689-012-9549-z  PMID:22829012 
  45. Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol. 2012;124(6):847-60. doi:10.1007/s00401-012-1034-0  PMCID:PMC3508279  PMID:22933014 
  46. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488(7409):49-56. doi:10.1038/nature11327  PMID:22832581 
  47. CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS One. 2012;7(3):e33005. doi:10.1371/journal.pone.0033005  PMCID:PMC3299723  PMID:22427929 
  48. Oligodendrogliomas in children. J Neurooncol. 2012;106(2):377-82. doi:10.1007/s11060-011-0674-6  PMID:21842314 
  49. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res. 2012;10(1):156-66. doi:10.1158/1541-7786.MCR-11-0411  PMCID:PMC3262072  PMID:22086906 
  50. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res. 2012;72(1):122-32. doi:10.1158/0008-5472.CAN-11-1701  PMCID:PMC3520097  PMID:22052462 
  51. Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys. 2011;80(4):1117-21. doi:10.1016/j.ijrobp.2010.03.013  PMID:21220190 
  52. Radiation therapy for pilocytic astrocytomas of childhood. Int J Radiat Oncol Biol Phys. 2011;79(3):829-34. doi:10.1016/j.ijrobp.2009.11.015  PMID:20421157 
  53. Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr. 2010;6(4):346-52. doi:10.3171/2010.7.PEDS10129  PMID:20887107 
  54. CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. J Neuroimmunol. 2010;224(1-2):108-13. doi:10.1016/j.jneuroim.2010.05.002  PMCID:PMC2910179  PMID:20554030 
  55. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res. 2010;70(14):5717-27. doi:10.1158/0008-5472.CAN-09-3769  PMCID:PMC2905483  PMID:20551058 
  56. Brainstem glioma presenting as pruritus in children with neurofibromatosis-1. J Pediatr Hematol Oncol. 2009;31(12):972-6. doi:10.1097/MPH.0b013e3181b8701f  PMID:19935099 
  57. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24):6215-24. doi:10.1182/blood-2008-05-158311  PMCID:PMC2699240  PMID:18955566 
  58. Morphine increases brain levels of ferritin heavy chain leading to inhibition of CXCR4-mediated survival signaling in neurons. J Neurosci. 2009;29(8):2534-44. doi:10.1523/JNEUROSCI.5865-08.2009  PMCID:PMC2664553  PMID:19244528 
  59. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009;27(3):385-9. doi:10.1200/JCO.2008.18.7724  PMCID:PMC2645855  PMID:19064966 
  60. Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression. Clin Cancer Res. 2008;14(23):7717-25. doi:10.1158/1078-0432.CCR-08-0827  PMCID:PMC2615415  PMID:19047098 
  61. Feasibility of small animal cranial irradiation with the microRT system. Med Phys. 2008;35(10):4735-43. doi:10.1118/1.2977762  PMCID:PMC2736759  PMID:18975718 
  62. Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr. 2008;2(2):125-9. doi:10.3171/PED/2008/2/8/125  PMCID:PMC2737696  PMID:18671617 
  63. Rethinking brain tumors: the fourth Mouse Models of Human Cancers Consortium nervous system tumors workshop. Cancer Res. 2008;68(14):5508-11. doi:10.1158/0008-5472.CAN-08-0703  PMCID:PMC2678167  PMID:18632599 
  64. Pathological expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am J Pathol. 2008;172(3):799-808. doi:10.2353/ajpath.2008.070918  PMCID:PMC2258272  PMID:18276777 
  65. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 2008;68(5):1520-8. doi:10.1158/0008-5472.CAN-07-5916  PMID:18316617 
  66. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1. Cancer Res. 2007;67(18):8588-95. doi:10.1158/0008-5472.CAN-06-2220  PMID:17875698 
  67. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res. 2007;67(2):651-8. doi:10.1158/0008-5472.CAN-06-2762  PMID:17234775 
  68. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology. 2006;67(8):1509-12. doi:10.1212/01.wnl.0000240076.31298.47  PMID:17060590 
  69. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res. 2005;65(24):11392-9. doi:10.1158/0008-5472.CAN-05-0847  PMID:16357147 
  70. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol. 2005;27(11):573-81. PMID:16282886 
  71. Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med. 2004;51(5):893-9. doi:10.1002/mrm.20029  PMID:15122670 
  72. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100(23):13513-8. doi:10.1073/pnas.2235846100  PMCID:PMC263845  PMID:14595012 
  73. Cerebellar proteoglycans regulate sonic hedgehog responses during development. Development. 2002;129(9):2223-32. PMID:11959830 
  74. BDNF stimulates migration of cerebellar granule cells. Development. 2002;129(6):1435-42. PMID:11880352 
  75. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics. 2002;109(2):E37. PMID:11826247 
  76. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development. 2001;128(11):1971-81. PMID:11493520 
  77. Molecular determinants of electrical rectification of single channel conductance in gap junctions formed by connexins 26 and 32. J Gen Physiol. 1999;114(3):339-64. PMCID:PMC2229461  PMID:10469726 
  78. Structure-function studies of voltage sensitivity of connexins, the family of gap junction forming proteins. Jpn J Physiol. 1993;43 Suppl 1:S301-10. PMID:8271512 
  79. A domain substitution procedure and its use to analyze voltage dependence of homotypic gap junctions formed by connexins 26 and 32. Proc Natl Acad Sci U S A. 1992;89(9):3820-4. PMCID:PMC525582  PMID:1315041 
  80. Molecular analysis of voltage dependence of heterotypic gap junctions formed by connexins 26 and 32. Biophys J. 1992;62(1):183-93; discussion 193-5. doi:10.1016/S0006-3495(92)81804-0  PMCID:PMC1260515  PMID:1376166 
  81. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res. 1987;18(2):299-304. doi:10.1002/jnr.490180206  PMID:3694713 
  82. Structural requirements for the transmembrane activation of the insulin receptor kinase. J Biol Chem. 1986;261(32):15281-7. PMID:3021769 
  83. The insulin receptor protein kinase. Physicochemical requirements for activity. J Biol Chem. 1983;258(23):14450-5. PMID:6557114 
  84. Stimulation of tyrosine-specific phosphorylation in vitro by insulin-like growth factor I. Nature. 1983;305(5933):438-40. PMID:6312321 
  85. 18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors. Neuro-Oncology Practice. 
  86. A Histone Deacetylase 3-Dependent Pathway Delimits Peripheral Myelin Growth and 2 Functional Regeneration 3 Nature Medicine. 
  87. Resistance promoting effects of ependymoma treatment revealed through genomic analyses of multiple recurrences in a single patient. Molecular Case Studies. 
  88. Pediatric Low-Grade Gliomas: A Brave New World. Neuro-Oncology. 
  89. Females have the survival advantage in glioblastoma. Neuro-Oncology. 
Last updated: 09/24/2018
© 2018 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130